The European Medicines Agency announced today that its human medicines committee provided a positive benefit-risk opinion on the use of the Dapivirine Vaginal Ring (DPV-VR) for HIV prevention. WHO stresses that when providing HIV prevention for women it is always critical to provide these alongside other services including STI diagnosis and treatment, HIV testing and links to antiretroviral therapy for all women who test positive and a range of contraception options.
Post a Comment